Ligand validation:6AM9

0JO: 2-{[(E)-{3-hydroxy-2-methyl-5-[(phosphonooxy)methyl]pyridin-4-yl}methylidene]amino}prop-2-enoic acid

0JO is a Ligand Of Interest in 6AM9 designated by the Author

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
6AM9_0JO_B_401	73%	57%	0.141	0.969	1.08	0.58	2	-	0	0	100%	1
6AM9_0JO_C_401	71%	73%	0.144	0.964	0.43	0.61	-	-	0	0	100%	1
6AM9_0JO_D_401	58%	57%	0.179	0.959	1.09	0.58	2	-	0	0	100%	1
5VM5_0JO_D_402	79%	15%	0.105	0.952	2.05	1.71	5	6	0	0	100%	1
3B1E_0JO_D_401	100%	19%	0.042	0.982	1.98	1.47	6	4	6	0	100%	1
7KYT_0JO_B_403	98%	51%	0.066	0.987	1.29	0.61	2	-	0	0	100%	1
4IY7_0JO_A_405	97%	10%	0.069	0.984	2.66	1.62	6	4	3	0	100%	1
7KWV_0JO_B_501	97%	48%	0.077	0.99	1.16	0.86	2	1	0	0	100%	1
4HPX_0JO_B_404	96%	16%	0.075	0.982	2.34	1.39	4	2	0	0	100%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.